Saint Noble Pharmaceuticals-B (02257.HK) announced its interim financial results, with a net loss attributable to shareholders of 3.698 million US dollars, a year-on-year decrease of 91%.

Zhitong Finance APP News, Shengnuo Medicine-B (02257.HK) released its 2025 interim performance, with other income of $124,000, a year-on-year decrease of 87.4%; the company's net loss attributable to owners was $3.698 million, a year-on-year decrease of 91%; basic loss per share was $0.04.